Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

Non-GAAP EPS Increased 22 Percent

CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, and strong progress across the company.

First-Quarter Highlights

-- Total revenue for the quarter grew 25 percent to $1.1 billion from

$883.2 million in same period a year ago. This increase was driven by

growth across all product lines, led by strong growth in sales of

treatments for lysosomal storage disorders and renal disease.

Genzyme's top line now includes sales of Aldurazyme(R) (laronidase),

which previously were recorded as joint venture revenue.

-- GAAP net income in the first quarter was $145.3 million, or $0.52 per

diluted share, compared with $158.2 million, or $0.57 per diluted

share. GAAP net income in this year's first quarter reflects an after-

tax charge of $56.5 million for the premium related to Genzyme's

strategic investment in Isis Pharmaceuticals Inc.

-- Non-GAAP net income increased 24 percent to $260.9 million, compared

with $210.7 million in the first quarter a year earlier. Non-GAAP

earnings increased 22 percent to $0.95 per diluted share from $0.78 per

diluted share in the first quarter last year.

-- Non-GAAP operating expenses decreased as a percentage of revenue,

reflecting global operating leverage.

-- Genzyme continued to generate significant cash from operations and to

reinvest in the future of the company. In the first quar
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015  Actavis plc (NYSE: ACT ) today ... Appeals for the Second Circuit has issued a ruling ... Company to continue distribution of NAMENDA ® (memantine ...   "While we are disappointed by ... to continue our strong efforts to convey the significant ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - SQI Diagnostics ... life sciences company that develops and commercializes proprietary technologies ... financial and operational results for the second fiscal quarter ... quarter the Company continued to advance business with our ... Andrew Morris , President and CEO of SQI. "The ...
(Date:5/21/2015)... May 21, 2015 uBiome, the ... a partnership with PicnicHealth, a healthcare company that ... diagnosed with Inflammatory Bowel Disease (IBD) will receive ... complementary uBiome research kit. Both companies were funded ... , For more information on this partnership ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
Breaking Biology Technology:Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... Bulletin Board: SNKTY), a Life Sciences company engaged in ... aging, today,announced that shareholders have approved all four resolutions ... of Shareholders held on,December 16, 2008. , ... results of the voting and we thank our,shareholders for ...
... Isis Pharmaceuticals,Inc. (Nasdaq: ISIS ) announces the following webcast: , , ... a subsidiary of Isis. Total acquisition price ... When: Wednesday, December 17, 2008 at 8:30 a.m. ET / ... Live on the Internet. Simply log onto our Web site listed, ...
... retina cells or other tissues can be tracked by ... record of movement and gene expression. The new technique, ... , will allow detailed analyses of correlations between behavior, ... team of researchers from the University of Southern California, ...
Cached Biology Technology:Senetek PLC Announces 2008 Annual General Meeting Voting Results 2Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences 2
(Date:4/20/2015)... The announcement comes as demand for fire vault ... Ireland,s foremost records management company, has secured ... impressive track record of clients within the first 12 months, ... sector in Dubai . As a result, ... a further eight staff members at its Irish headquarters. The ...
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... male birds attract more females and as a result are ... point of many studies looking for factors that influence sexual ... birds see what we see? In a study published in ... our human vision is not an adequate instrument. The ...
... the late 19th century the Czech scientist Franz Hofmeister ... of proteins in egg white, some caused the proteins ... between these poles. Hofmeister proceeded to rank ... magnitude of their effects. The resulting "Hofmeister series" governs ...
... release is available in Spanish . ... but somebody, or at least some dogs, have to do ... trained to detect animal feces by scent are helping researchers ... anteater and maned wolf in and around Emas National Park, ...
Cached Biology News:Human vision inadequate for research on bird vision 2New clues to how proteins dissolve and crystallize 2New clues to how proteins dissolve and crystallize 3New clues to how proteins dissolve and crystallize 4Can feces save the species? 2Can feces save the species? 3
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
GOAT ANTI HUMAN FACTOR 8RELATED ANTIGEN...
Biology Products: